<DOC>
	<DOCNO>NCT01488266</DOCNO>
	<brief_summary>The objective study compare efficacy safety aripiprazole adjunctive therapy versus switch different class antidepressant treat major depressive disorder partially minimally responsive ongoing antidepressant treatment .</brief_summary>
	<brief_title>Aripiprazole Augmentation Versus Switching Different Class Antidepressants Major Depressive Disorder</brief_title>
	<detailed_description>Most guideline suggest nonresponders partial responder consider switch , combination augmentation treatment . Traditional augmentation agent , lithium , triiodothyronine ( T3 ) , buspirone , dopamine agonist , stimulant commonly use patient population limit support data . Recently , augmentation atypical antipsychotic antidepressant therapy become commonly accept treatment practice . This strategy proven useful enhancement antidepressant effect , show increased remission rate early treatment effect core depressive symptom , comorbid symptom well antidepressant- mediated side effect ( e.g. , sexual dysfunction ) . Although , limited treatment option treat patient describe , clear treatment option would best acceptable patient clinical practice yet . Among augmentation agent , aripiprazole first drug approve U.S. FDA . augmentation therapy antidepressant treatment patient MDD show imminent efficacy reliable safety profile adequately-powered well-designed control clinical trial .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients older 20 year age diagnosis MDD without psychotic feature , define DSMIVTR . Patients report inadequate response current antidepressant treatment . Inadequate response antidepressant define : total score HDRS17 14 ) , despite adequate dose current antidepressant treatment least 6 week current episode ( coadministered ATRQ ) Classification antidepressant include study ( list suggestion ) : Escitalopram 10~20mg/day , fluoxetine 20~40mg/day , paroxetine control release ( CR ) 25~62.5mg paroxetine 20~40mg , sertraline 100~150mg , bupropion XL ( SR ) 150~300mg , mirtazapine 15~45mg , venlafaxine immediate extend release ( IR ER ) 112.5~225mg/day , duloxetine 60mg [ criterion generic medication brand drug ] Those first episode , drug naive MDD subject Those current Axis I diagnosis delirium , dementia , amnestic cognitive disorder , schizophrenia psychotic disorder , bipolar 1 2 disorder , eat disorder , obsessivecompulsive disorder , panic disorder , posttraumatic stress disorder Those clinically significant current Axis 2 diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder Those experience hallucination , delusion , psychotic symptomatology current depressive episode Those meet DSMIVTR criterion significant substance use disorder within past 12 month ( except nicotine ) Those know allergy , hypersensitivity previous unresponsiveness aripiprazole know intolerance study medication Those cognitivebehavioral therapy psychotherapy , potential need treat study period Those complicate serious medical problem , severe renal , hepatic dysfunction , cardiovascular , lung , gastrointestinal , endocrine , nervous , infectious disease , neoblastic , metabolic disease Those show previous unresponsiveness adequate antidepressant trial 2 episode 3 antidepressant treatment Those chronic liver renal disease Those pregnant brestfeeding Those participated clinical trial aripiprazole investigational product within past month ( include randomize , doubleblind , placebocontrolled openlabel study ; chart review , observational study enrol ) Those history thyroid pathology , neuroleptic malignant syndrome , serotonin syndrome Those received adjunctive antipsychotic plus antidepressant 3 week current episode Those receive electroconvulsive therapy current episode Those show inadequate response previous ECT episode Those suicidal risk Those likely require prohibit concomitant therapy trial Those receive treatment monoamine oxidase inhibitor within 2 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>depression</keyword>
	<keyword>depressive</keyword>
	<keyword>major</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>switch</keyword>
	<keyword>augmentation</keyword>
	<keyword>antidepressant</keyword>
</DOC>